持续热灌注腹腔化疗联合静脉化疗治疗进展期胃肠肿瘤的临床研究被引量：12

导出

摘要目的为了探索进展期胃肠肿瘤的有效治疗方法,对持续热灌注腹腔化疗(Hyperthermic intraperitoneal chemoperfusion,HIPC)、腹腔化疗和单纯静脉化疗进行临床研究和初步疗效评价.方法回顾性分析了1999年9月～2003年10月住院进展期胃肠肿瘤患者53例,分别接受HIPC+静脉化疗(HIPC+IVC,14例)、单纯静脉化疗(SIVC,21例)和常规腹腔化疗+静脉化疗(IPC+IVC,18例)3种治疗方法,治疗2个周期以上,分析其疗效差异.结果与IPC+IVC组或SIVC组相比,HIPC+IVC组病人缓解率、总体疗效有明显差异(P＜0.05),且在治疗转移性腹水方面有明显的优势(P＜0.05),但对肝转移灶缩小方面的疗效优势不能肯定(P＞0.05).引起全身副作用比SIVC组小,对机体的免疫打击小.患者生活质量改善明显,临床受益率高.结论对于进展期胃肠肿瘤患者,HIPC+IVC疗效好,副作用小,患者住院天数少,平均住院费低,收益/投入高.

作者赵艳杰王睿斌乔士峰

机构地区北京铁路总医院

出处《临床医学》 CAS 2005年第9期34-36,共3页 Clinical Medicine

关键词胃肠肿瘤腹腔化疗热灌注静脉化疗化疗治疗临床研究进展期肿瘤患者联合治疗方法

分类号 R735 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1中国卫生年鉴编委会.中国卫生年鉴[M].北京:人民卫生出版社,1995.413.
2中华人民共和国卫生部医政司编.中国常见恶性肿瘤诊治规范第九分册[M].北京:北京医科大学中国协和医科大学中国联合出版社,1991.10～15.
3Zeamari S, Floot B,Van der Vange N,et al. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion ( HIPEC ). Anticancer Res ,2003,23 (2 B ): 1643 - 1648.
4Witkamp AJ,de Bree E, Kaag MM,et al. Extensive cytoreductive surgery followed by intra- operative hyperthermic intraperitoneal chemotherapy with mitomycin - C in patients with peritoneal carcinomatosis of colorectal origin. Ur J Cancer,2001,37(8) :979 -84.
5McOuellon RP, Loggie BW, Fleming RA, et al. Quality of life after intraperitoneal hyperthermic chemotherapy ( IPHC ) for peritoneal carcinomatosis. Eur J Surg Oncol,2001,27( 1 ) :65 - 73.
6Miller AB, Hoogstratraten B, Staquet M,et al. Reporting results of cancer treatment.Cancer,1981,47.207.
7Zeamari S,Floot B, van der Vange N, et al. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion ( HIPEC ). Anticancer Res,2003,23 (2B): 1643 - 8.
8Ruth S, Mathot RA,Sparidans R W,et al. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet, 2004,43 ( 2 ): 131 - 43.
9Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res,2002,22 (2B): 1329 - 36.